US FDA Gains Budget Increase In FY 2017…And Not Through Fees
Omnibus legislation to fund the federal government for the remainder of FY 2017 includes a switch from what has been a growing trend of FDA's increasing reliance on industry user fees as opposed to congressional appropriations. Non-user-fee budget authority will grow, while fee amounts dropped for the fiscal year.
You may also be interested in...
Confirmation comes with fewest votes of any recent commissioner as FDA dealing with budget, user fees and other issues.
FDA's device center 'has a lot of work ahead of us,' to implement not only the 21st Century Cures Act, but also maintain performance goals for device and drug reviews, speakers said at a Food Drug Law Institute meeting May 5. The agency released a proposed work plan for use of 'Cures' Innovation Account funds, with dollars detailed for the device side on breakthrough devices, humanitarian device exemptions, and least burdensome device provisions, among others, as spelled out for use at a May 8-9 Science Board meeting.
With a little more than a week left for Congress to extend government funding, US FDA and HHS plan for furloughs should no new appropriations be enacted.